전환 가능한 CAR, 로직 게이트 세포 회로, 생체내 CAR 프로그래밍 및 차세대 면역 공학 - 기술, 파이프라인 및 시장 전망(2025-2045년)

Executive Summary / Description

Programmable cell therapies (PCT) move beyond static, single-antigen CAR-T toward software-like immune cells whose behavior can be turned on/off, re-routed, combined, or rewritten in vivo. The stack spans:

• Switchable CARs (drug- or adaptor-titrated on/off; universal CARs using soluble adaptors such as scFv-Fc, Fabs, or tagged ligands).
• Logic-gated circuits (AND, OR, NOT, NAND) using SynNotch, split CARs, AND-gate receptors, inhibitory CARs (iCARs), and microRNA target de-masking.
• In-vivo programming (LNP/VLP delivery of CAR cassettes directly to T/NK cells; transient RNA CARs; hematopoietic in-situ reprogramming).
• Cell types beyond autologous T (allogeneic/"off-the-shelf" T; NK, macrophage/monocyte (CAR-M), YδT, invariant NKT).
• Safety governance (drug-inducible suicide switches, protease "safety caps", cytokine rheostats, kill-switchable gene circuits).
• Microenvironment mastering (dominant-negative TGFBR2, armored cytokines like IL-12/IL-18/IL-7/CCL19, CXCR4/CXCR5 homing edits; matrix-degrading modules).
• Manufacturing 2.0 (closed systems, non-viral integration, CRISPR/Prime knock-ins at TRAC/CCR5, perfusion bioreactors, automated analytics).

Why it matters

• Solid tumors remain the big prize; programmability is the unlock (antigen heterogeneity, immune suppression, trafficking barriers).
• Toxicity control via dosing knobs & logic reduces CRS/ICANS risk and broadens outpatient delivery.
• Cost & access improve through allogeneic and in-vivo approaches (no apheresis, faster turnaround, scalable COGS).
• Label expansion in autoimmunity (CD19/BCMA precedents), fibrosis, and infectious disease becomes credible with precise control circuits.

Market outlook (risk-adjusted): from ~$6-8B in 2024 (largely heme CAR-T) to $40-60B by 2035 and $90-130B by 2045, with upside contingent on:

• First logic-gated solid-tumor wins,
• Allogeneic persistence + low GvHD profile,
• In-vivo CAR clinical validation (redoseable RNA/VLP),
• Payer acceptance of ambulatory administration & bundled episode payments.

Technology Understanding

1) Control Layers

• Input control: adaptor-titrated universal CARs (e.g., anti-tag CAR + soluble "bridging" adaptors to any antigen), drug-inducible on/off switches (rimiducid-like domains, PROTAC-degron CARs), split signal domains that dimerize with small molecules.
• Computation: SynNotch -> CAR (IF Antigen A THEN express CAR-B), AND-gate (two co-receptors required), NOT-gate/iCAR (suppress if normal-tissue antigen present), microRNA de-targeting (silence CAR in healthy tissues).
• Output shaping: cytokine rheostats (tunable IL-2/IL-12/IL-18), chemokine rewiring (CXCR1/2/4/5), metabolic rewrites (PDH/GLUT1 tuning), exhaustion-resistant edits (PDCD1, TOX programs).
• Failsafes: iCasp9 suicide, FKBP/Degron degradation tags, logic "dead-man" switches.

2) Modalities & Cell Types

• T cells (auto & allo), NK (KIR/KLRC logic, ADCC synergy), CAR-M (innate phagocytosis + antigen presentation), YδT, iNKT, Treg (autoimmune tolerance).
• In-vivo programming: LNP-mRNA CAR to circulating T/NK; VLP-delivered gene writers to hematopoietic subsets; transient RNA-CAR dosing.
• Insertion sites: TRAC (uniform expression, reduced tonic signaling), CCR5, Rosa26; non-viral knock-ins (CRISPR/prime editors; transposase HELIX/piggyBac).

3) Solid-Tumor Toolkit

• Multi-antigen targeting (CLDN18.2, GD2, HER2-low, EGFRvIII, MUC1*, GPC3, mesothelin, PSMA, B7-H3).
• TME remodeling: heparanase, hyaluronidase modules; matrix-sensing SynNotch; dominant-negative TGFBR2; CD47/SIRPa checkpoint for CAR-M.
• Trafficking: chemokine receptor edits to match tumor secretome; oncolytic-virus pre-conditioning; regional delivery (intra-pleural, intra-hepatic).

Table of Content

1. Introduction & Scope

• 1.1 Definition of Programmable Cell Therapies (PCT)
• 1.2 From fixed CAR-T -> software-defined cell drugs
• 1.3 Methodology, datasets, evidence grading

2. Cell Engineering Architecture

• 2.1 CAR design basics refresher
• 2.2 Switchable CARs
• 2.3 Logic-gated circuits
• 2.4 Armored CARs & rheostats
• 2.5 Safety frameworks
• 2.6 Manufacturing 2.0

3. Cell Types & Comparative Biology

• 3.1 Autologous aB T cells
• 3.2 Allogeneic T cells (TCR knockout; HLA-E/CIITA edits)
• 3.3 NK cells (CNS penetration potential; innate activation)
• 3.4 CAR-Macrophages (phagocytosis, antigen presentation, stromal editing)
• 3.5 YδT and iNKT (MHC-independent recognition)
• 3.6 Treg programming for autoimmunity & transplant tolerance

4. In-Vivo Programming

• 4.1 LNP-mRNA CAR delivery to circulating lymphocytes
• 4.2 VLP-mediated gene insertion; viral-free editors
• 4.3 Transient RNA-CAR vs genomic CAR (PK/PD, redoseability)
• 4.4 Organ-targeted delivery (liver, lung, lymphoid tissues)
• 4.5 Regulatory and CMC implications of in-vivo cell therapy

5. Target & Indication Maps

• 5.1 Hematologic malignancies - consolidation & relapse prevention
• 5.2 Solid tumors - multi-antigen, regional delivery, TME defenses
• 5.3 Autoimmunity (CD19, BCMA, CD5, CD45 pathfinding)
• 5.4 Fibrosis & organ repair adjacencies (experimental)
• 5.5 Infectious diseases (HBV cccDNA niches, HIV reservoirs - research)

6. Clinical Development Landscape

• 6.1 Global pipeline census (auto vs allo; T/NK/M; in-vivo CAR)
• 6.2 Registrational & pivotal programs
• 6.3 Early-signal readouts for logic & switchable constructs
• 6.4 Safety learning (CRS/ICANS, on-target off-tumor, allo risks)

7. Competitive & Deal Landscape

• 7.1 Licensing heatmap
• 7.2 M&A outlook

8. Forecasts & Scenarios (2025-2045)

• 8.1 TAM/SAM for heme, solid, autoimmune
• 8.2 Base/Bull/Bear adoption curves
• 8.3 Share shift: auto -> allo -> in-vivo

9. Appendix